[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 19, Issue 6 (Iranian South Medical Journal 2017) ::
Iran South Med J 2017, 19(6): 1011-1021 Back to browse issues page
The Correlation of Adiponectin, and Visfatin Serum Levels With Ischemic Heart Disease in Postmenopausal women: A population-Based Study
Hossein Darabi1, Zahra Behzadi1, Taliaeh Zahedi1, Mohammadreza Pourbehi1, Samad Akbarzadeh1, Afshin Ostovar1, Majid Assadi2, Mohammad Javad Haerinejad1, Zahra Sanjideh1, Iraj Nabipour 3
1- The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
2- The Persian Gulf Nuclear Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
3- The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran , inabipour@gmail.com
Abstract:   (3601 Views)

Background: There is a controversial evidence about adiponectin role in cardiovascular diseases and visfatin role has been suggested in pathogenesis of coronary artery disease.

Material and Methods: A total of 378 postmenopausal women were randomly selected from 13 clusters in Bushehr Port. The prevalence of ischemic heart disease was assessed by using the Minnesota Code with a 12-lead resting electrocardiogram (EKG). Serum adiponectin and visfatin levels were measured by using enzyme-linked immunosorbent assay methods

Results: A total of 159 patients (41.8 percent) were suffering from ischemic heart disease. There was no significant difference between women with ischemic heart disease and healthy postmenopausal women in adiponectin serum level. However, diabetic women with ischemic heart disease, compared with healthy postmenopausal women had a higher level of visfatin (Geometric Mean: 3.05±1.84 ng/ml versus 2.52±1.90 ng/ml, respectively; p=0.023). Multiple logistic regression analysis indicated that higher serum levels of visfatin were significantly associated with a higher prevalence of ischemic heart disease after adjusting for potential confounders, including classical cardiovascular risk factors and circulating hs-CRP levels [odds ratio=3.26, confidence interval (1.14-9.68), p=0.027].

Conclusion: Adiponectin was not correlated with ischemic heart disease among postmenopausal women. But visfatin serum level correlated with ischemic heart disease in postmenopausal non-diabetic women independently from cardiovascular risk factors.

Keywords: Menopause, Adiponectin, Visfatin, Ischemic Heart Disease, Adipocytokines
Full-Text [PDF 798 kb]   (902 Downloads)    
Subject: Disorders of Systemic, Metabolic or Environmental Origin
Received: 2017/01/21 | Accepted: 2017/01/21 | Published: 2017/01/21
1. Nanayakkara G, Kariharan T, Wang L, et al. The cardio-protective signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2012; 2(4): 253-66. [PubMed] [Google Scholar]
2. Lindberg S, Mogelvang R, Pedersen SH, et al. Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am J Cardiol 2013; 111(8): 1139-45. [PubMed] [Google Scholar]
3. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291(14): 1730-7. [PubMed] [Google Scholar]
4. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23(1): 85-9. [PubMed] [Google Scholar]
5. Barseghian A, Gawande D, Bajaj M. Adiponectin and vulnerable atherosclerotic plaques. J Am Coll Cardiol 2011; 57(7): 761-70. [PubMed] [Google Scholar]
6. Zhang Y, Zhao J, Li R, et al. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. Am J Physiol Endocrinol Metab 2015; 309: E275-82. [PubMed] [Google Scholar]
7. De Roeck L, Vandamme S, Everaert BR, et al. Adiponectin and ischemia-reperfusion injury in ST segment elevation myocardial infarction. Eur Heart J Acute Cardiovas Care 2016; 5(1): 71-6. [PubMed] [Google Scholar]
8. Sook Lee E, Park SS, Kim E, et al. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol 2013; 42(4): 1029-39. [PubMed] [Google Scholar]
9. Hao G, Li W, Guo R, et al. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of 17 prospective studies. Atherosclerosis 2013; 228(1): 29-35. [PubMed] [Google Scholar]
10. Sawicka M, Janowska J, Chudek J. Potential beneficial effect of some adipokines positively correlated with the adipose tissue content on the cardiovascular system. Int J Cardiol 2016; 222: 581-9. [PubMed] [Google Scholar]
11. Romacho T, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm 2013; 2013: 946427. [PubMed] [Google Scholar]
12. Mazaherioun M, Hosseinzadeh-Attar MJ, Janani L, et al. Elevated serum visfatin levels in patients with acute myocardial infarction. Arch Iran Med 2012; 15(11): 688-92. [PubMed] [Google Scholar]
13. Wang XH, Dou LZ, Gu C, et al. Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure. Asian Pac J Trop Med 2014; 7(1): 55-62. [PubMed] [Google Scholar]
14. Lu YC, Hsu CC, Yu TH, et al. Association between visfatin levels and coronary artery disease in patients with chronic kidney disease. Iran J Kidney Dis 2013; 7(6): 446-52. [PubMed] [Google Scholar]
15. Shojaei M, Kalantarhormozi MR, Akbarzadeh S, et al. Correlation between serum adiponectin level and the metabolic syndrome in postmenopausal women: a population-based study. Iran South Med J 2013; 16(5): 276-87. (Persian) [Google Scholar]
16. Pourbehi MR, Zahedi T, Darabi H, et al. Omentin-1 and nonfatal ischemic heart disease in postmenopausal women: a population-based study. Endocr Pract 2016; 22(7): 780-5. [PubMed] [Google Scholar]
17. WHO MONICA Project, MONICA manual. (Accessed at http://www.ktl.fi/publications/monica/manual/index.htm)
18. Prineas RJ, Crow RS, Blackburn HW. The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. 1982. [Google Scholar]
19. Choudhury SR, Yoshida Y, Kita Y, et al. Association between electrocardiographic ischemic abnormalities and ischemic heart disease risk factors in a Japanese population. J Hum Hypertens 1996; 10(4): 225-34. [PubMed] [Google Scholar]
20. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20(7): 1183. [PubMed] [Google Scholar]
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97. [PubMed] [Google Scholar]
22. Lu JY, Huang KC, Chang LC, et al. Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci 2008; 15(5): 565-76. [PubMed] [Google Scholar]
23. Kizer JR, Benkeser D, Arnold AM, et al. Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. J Clin Endocrinol Metab 2013; 98(1): 255-63. [PubMed] [Google Scholar]
24. Rothenbacher D, Brenner H, März W, et al. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005; 26(16): 1640-6. [PubMed] [Google Scholar]
25. Tomicek NJ, Hunter JC, Machikas AM, et al. Acute adiponectin delivery is cardioprotective in the aged female rat heart. Geriatr Gerontol Int 2015; 15(5): 636-46. [PubMed] [Google Scholar]
26. Hognogi LD, Simiti LV. The cardiovascular impact of visfatin-an inflammation predictor biomarker in metabolic syndrome. Clujul Med 2016; 89(3): 322-6. [PubMed] [Google Scholar]
27. Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2010; 118(2): 75-80. [PubMed] [Google Scholar]
28. Liu SW, Qiao SB, Yuan JS, et al. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009; 71(2): 202-7. [PubMed] [Google Scholar]
29. Fadaei R, Parvaz E, Emamgholipour S, et al. The mRNA Expression and Circulating Levels of Visfatin and Their Correlation with Coronary Artery Disease Severity and 25-Hydroxyvitamin D. Horm Metab Res 2016; 48(4): 269-74. [PubMed] [Google Scholar]
30. Hung WC, Yu TH, Hsu CC, et al. Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction. Clin Invest Med 2015; 38(3): E100-9. [PubMed] [Google Scholar]
31. Yang Y, Li Z, Tao HF, et al. An elevated plasma level of visfatin increases the risk of myocardial infarction. Genet Mol Res 2014; 13(4): 8586-95. [PubMed] [Google Scholar]
32. Saddi-Rosa P, Oliveira CS, Giuffrida FM, et al. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010; 2: 21. [PubMed] [Google Scholar]
33. Macfarlane PW, Norrie J, Committee WE. Looking for prognostic information in the ST-T segment--is it really worth it. J Electrocardiol 2004; 37: 209-13. [PubMed] [Google Scholar]
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Darabi H, Behzadi Z, Zahedi T, Pourbehi M, Akbarzadeh S, Ostovar A, et al . The Correlation of Adiponectin, and Visfatin Serum Levels With Ischemic Heart Disease in Postmenopausal women: A population-Based Study. Iran South Med J. 2017; 19 (6) :1011-1021
URL: http://ismj.bpums.ac.ir/article-1-850-en.html

Volume 19, Issue 6 (Iranian South Medical Journal 2017) Back to browse issues page
دانشگاه علوم پزشکی بوشهر، طب جنوب ISMJ

Iranian South Medical Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License which allows users to read,
copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly

Copyright © 2017, Iranian South Medical Journal| All Rights Reserved

Persian site map - English site map - Created in 0.07 seconds with 31 queries by YEKTAWEB 4111